IQVIA vs Accenture

IQVIA Holdings Inc. and Accenture PLC are two reputable companies in the technology and healthcare industries, both listed on the stock market. IQVIA specializes in providing data and analytics solutions to the healthcare sector, while Accenture is a global consulting and technology services firm. Investors looking to diversify their portfolio may consider investing in these companies due to their strong market positions and potential for growth. Analysis of their financial performance, market trends, and competitive advantages can help investors make informed decisions about investing in IQVIA vs. Accenture stocks.

IQVIA or Accenture?

When comparing IQVIA and Accenture, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between IQVIA and Accenture.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. IQVIA has a dividend yield of -%, while Accenture has a dividend yield of 1.85%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. IQVIA reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Accenture reports a 5-year dividend growth of 10.76% year and a payout ratio of 44.57%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with IQVIA P/E ratio at 29.83 and Accenture's P/E ratio at 32.14. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. IQVIA P/B ratio is 6.32 while Accenture's P/B ratio is 8.25.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, IQVIA has seen a 5-year revenue growth of 0.60%, while Accenture's is 0.54%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with IQVIA's ROE at 22.79% and Accenture's ROE at 26.46%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $231.84 for IQVIA and $365.43 for Accenture. Over the past year, IQVIA's prices ranged from $167.42 to $261.73, with a yearly change of 56.33%. Accenture's prices fluctuated between $278.69 and $387.51, with a yearly change of 39.05%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.